Search
Iodide I-131
go.drugbank.com/drugs/DB09293ApprovedInvestigationalIodine-131 is notable for causing mutation and death in cells that it penetrates, which is due to its mode of beta decay. … It is also indicated for use in performance of the radioactive iodide (RAI) uptake test to evaluate thyroid function.
Products: Natriumjodid (131I) Curium - Kapsel TGimeracil
go.drugbank.com/drugs/DB09257ApprovedInvestigationalIt functions by reversibly and selectively blocking the enzyme dihydropyrimidine dehydrogenase (DPD), which is involved in the degradation of 5-FU [A31408]. … The main active ingredient in Teysuno is [DB09256], a pro-drug of [DB00544] (5-FU), which is a cytotoxic anti-metabolite drug that acts on rapidly dividing cancer cells.
Synonyms: Ts-1 (TN)Xanthine
go.drugbank.com/drugs/DB02134InvestigationalThe methylated xanthine compounds caffeine, theobromine, and theophylline and their derivatives are used in medicine for their bronchodilator effects. (Dorland, 28th ed) … It is an intermediate in the degradation of adenosine monophosphate to uric acid, being formed by oxidation of hypoxanthine.
Mixtures: NECROTON CONCENTRADO 30 MGClonidine
go.drugbank.com/drugs/DB00575ApprovedInvestigationalClonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors.[A180559] This activity is useful for the treatment of hypertension, severe pain, and ADHD. … [L7237,L54536,L7240,L7243,L7246] Clonidine was granted FDA approval on 3 September 1974.[L7237]
Categories: Sympathomimetics in Glaucoma TherapySynonyms: 2,6-Dichloro-N-2-imidazolidinylidenebenzenamineLevopropoxyphene
go.drugbank.com/drugs/DB06793ApprovedWithdrawnLevopropoxyphene is a stereoisomer of propoxyphene in the form of 2S, 3R enantiomer. It was sold as an antitussive, but it was removed from the market in the 70s. … [T133] Levopropoxyphene was developed by Lilly and FDA approved on March 21st, 1962. This drug presented different dosages and it was administered as a capsule or suspension.
Saquinavir
go.drugbank.com/drugs/DB01232ApprovedInvestigationalIn 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared … Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection.
Products: SAQUINAVIR 500 MG TABLETAS., SAQUINAVIR 500 MG TABLETA RECUBIERTAVelmanase alfa
go.drugbank.com/drugs/DB12374ApprovedInvestigational[L39744] It was granted marketing authorization by the European Commission in March 2018 under the market name Lamzede [L39754] as the first human recombinant form of alpha-mannosidase for the treatment … Patients with alpha-mannosidosis have a genetic mutation that causes a deficiency in the lysosomal enzyme alpha-mannosidase, which is an enzyme responsible for breaking down complex sugars in the body.
Hydroxychloroquine
go.drugbank.com/drugs/DB01611ApprovedInvestigational[L8072] It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. … [L8072] It was developed during World War II as a derivative of [quinacrine] with less severe side effects.
Synonyms: 7-chloro-4-[5-(N-ethyl-N-2-hydroxyethylamino)-2-pentyl]aminoquinoline, 7-chloro-4-(4-(N-ethyl-N-β-hydroxyethylamino)-1-methylbutylamino)quinolineProducts: ARTROQUIN 400 MG, ARTROQUIN 200 MGFidanacogene elaparvovec
go.drugbank.com/drugs/DB16783ApprovedInvestigational[A32552] Disease severity is linked to the level of factor IX activity in the blood plasma, ranging from increased bleeding after injuries and surgical operations to spontaneous bleeding, hemorrhages in … from week 12 to month 15 compared to an ABR of 4.43 for the pre-treatment period.
Roflumilast
go.drugbank.com/drugs/DB01656ApprovedInvestigational[L46546] It was first approved by the EMA in July 2010, and by the FDA in January 2018.[L37564] Roflumilast topical cream is indicated to treat plaque psoriasis. … [A251385] The resultant increase in intracellular cAMP induced by roflumilast's inhibition of PDE4 is thought to mediate its disease-modifying effects, although its precise mechanism of action has yet
Products: ROFLUNG 0,5 MG SAŞE ,30 SAŞE, ROFLUNG 0,5 MG SAŞE ,90 SAŞE